Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC8A1 | P32418 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664869 | 0.91 | MEN1 (0.39) | SLC8A1RAB9ASPRP2RX7 | |
| SCHEMBL4964984 | 0.89 | RAB9A (0.39) | SLC8A1RAB9ASPRATM | |
| SCHEMBL4664623 | 0.89 | RAB9A (0.39) | SLC8A1RAB9ASPRATM | |
| SCHEMBL4666535 | 0.89 | RAB9A (0.39) | SLC8A1RAB9ASPRATM | |
| SCHEMBL5657872 | 0.88 | PLAUR (0.40) | SLC8A1RORCHPGD | |
| SCHEMBL6020045 | 0.85 | DHODH (0.36) | SLC8A1RAB9A | |
| SCHEMBL6019450 | 0.85 | DHODH (0.36) | SLC8A1RAB9A | |
| SCHEMBL4663178 | 0.85 | DHODH (0.36) | SLC8A1RAB9A | |
| SCHEMBL5506543 | 0.84 | RAB9A (0.35) | SLC8A1RAB9A | |
| SCHEMBL4666543 | 0.84 | RAB9A (0.35) | SLC8A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | claimed |
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| EP-1613626-A1 | CYCLIC BENZIMIDAZOLES | ALTANA Pharma AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087701-A1 | CYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | SLC8A1 3552/4885RAB9A 2004/4885NPC1 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.